KinDex was established in the fall of 2009 to focus on the discovery and development of molecules that modulate key regulatory networks associated with chronic disease. The principle targets for KinDex are the regulatory nodes embedded in signaling networks that control genetic expression patterns associated with insulin resistance, Type 2 diabetes, cardio-metabolic syndrome and obesity. KinDex has a portfolio of lead molecules that have demonstrated a novel mechanism of action in their ability to safely normalize the disturbed regulatory networks related to the etiology of Type 2 diabetes and obesity.